by CN Bio. | May 5, 2021 | Press releases
The FDA expands collaboration with CN Bio to investigate lung-on-a-chip model for inhaled drug evaluation applications Extension aims to evaluate CN Bio’s PhysioMimix lung-on-a-chip platform in addition to deepening existing research collaboration for liver studies...
by CN Bio. | Mar 17, 2021 | Press releases
CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip (OOC), today announced the commercial launch of its new PhysioMimix™ OOC Multi-Organ MPS. The next-generation platform combines CN Bio’s in vitro...
by CN Bio. | Mar 1, 2021 | Press releases
Funding will advance 3D lung cell culture models to accelerate drug discovery CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip, today announced it has received a grant from Innovate UK, the UK’s...
by CN Bio. | Jan 11, 2021 | Press releases
FDA publication demonstrates advantages of PhysioMimix™ in drug safety and metabolism applications, over standard techniques Represents the first co-published, peer-reviewed article between a microphysiological system provider and a regulator Characterizing the...
by CN Bio. | Dec 15, 2020 | Press releases
CN Bio’s Lung-on-a-Chip technology will enable research into therapies to prevent interstitial lung disease and long-term lung impairment, following SARS-CoV-2 infection CN Bio, a leading cell culture company, that has developed single and multi-organ...
by CN Bio. | Oct 27, 2020 | Press releases
Extended range of services supports accelerated drug discovery and development using predictive 3D Liver-on-Chip technology CN Bio, a leading 3D cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy...
